Cipla Limited

Cipla Limited

Cipla Limited has informed the Exchange about the outcome of the USFDA inspection at its InvaGen manufacturing facility in Central Islip, Long Island, NY, USA, which has been classified as Voluntary Action Indicated (VAI).

Cipla Limited

Cipla Limited has informed the Exchange about Other Restructuring, where Aspergen Limited, India, a 60:40 joint venture between the Company and Kemwell Biopharma Private Limited, has acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary of the Company, from Cipla (EU) Limited (holding 60% stake), a wholly owned subsidiary of the Company, and Kemwell Biopharma UK Limited (holding 40% stake). Consequently, Aspergen Inc., USA has become a wholly owned subsidiary of Aspergen Limited, India. There is no change in the Company's economic interest in Aspergen Inc., USA, pursuant to the aforesaid restructuring.

Cipla Limited

Cipla Limited has informed the Exchange about the schedule of Analyst / Institutional Investor Meetings with the Company.

Cipla Limited

Cipla Limited has informed the Exchange regarding the allotment of 5281 shares under the Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021. The issued, subscribed, and paid-up share capital of the Company stands increased to INR 161,57,16,894 comprising of 80,78,58,447 equity shares of face value INR 2 each.

Cipla Limited

Cipla Limited has informed the Exchange about a USFDA inspection at its manufacturing facility in Pithampur, India, where seven inspectional observations were noted in Form 483. The company will work with the USFDA to address these observations comprehensively within the stipulated time.

Cipla Limited

Cipla Limited has informed the Exchange about receipt of order from Hon'ble NCLT, Mumbai Bench, allowing the Scheme of Amalgamation of Inzpera Healthsciences Limited with Cipla Limited.

Cipla Limited

Cipla Limited has been assigned ESG ratings by SES ESG Research Private Limited and NSE Sustainability Ratings & Analytics Limited. SES assigned a rating of 69.9 (Grade B) for FY 2025-26, a slight improvement from 69.3 (Grade B) for FY 2024-25. NSE assigned a rating of 67 (Aspiring) for FY 2025-26, a decline from 69 (Aspiring) for FY 2024-25, potentially due to a product recall by Cipla USA Inc.

Cipla Limited

Cipla Limited has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection at its InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA.

Cipla Limited

Cipla Limited has informed the Exchange regarding allotment of 7850 securities pursuant to ESOP/ESPS at its meeting held on July 31, 2026. The issued, subscribed and paid-up share capital of the Company stands increased to INR 1,61,57,06,332 comprising of 80,78,53,166 equity shares of face value INR 2 each.

Cipla Limited

Cipla Limited has received US FDA approval for its Generic Advair Diskus, a dry powder inhaler for asthma and COPD treatment, marking a significant milestone in the company's expansion of complex respiratory capabilities in the US.

Cipla Limited

Cipla Limited has released the transcript of its Q1 FY27 earnings conference call, which was held on July 23, 2026. The company reported its highest ever Q1 revenue with revenues of INR7,100 crores, driven by strong performance across key therapies and a diversified business.

Cipla Limited

Cipla Limited has informed the Exchange about the unaudited financial results for the quarter ended 30th June, 2026. The results have been published in Business Standard (English) and Sakal (Marathi).

Cipla Limited

Cipla Limited has informed the Exchange about the link of recording of earnings conference call for the quarter ended 30th June, 2026, available on the Company’s website.

Cipla Limited

Cipla Limited has informed the Exchange that the Board has approved the changes in the Key Managerial Personnels (KMPs) and Officers authorised under Regulation 30(5) of the SEBI Listing Regulations.

Cipla Limited

Cipla Limited has informed the Exchange regarding the grant of stock options and employee stock appreciation rights under the Employee Stock Option Scheme 2013 A and the Cipla Employee Stock Appreciation Rights Scheme 2021.

Cipla Limited

Cipla Limited has informed the Exchange about change in management. Mr. Sanjay Joseph, Head – API Business, will cease to be Senior Managerial Personnel (SMP) with effect from 24th July, 2026.

Cipla Limited

Cipla Limited has informed the Exchange regarding Outcome of Board Meeting held on July 23, 2026. The Board of Directors has approved the transition of Mr. Ashish Adukia to an internal business leadership role, and the appointment of Mr. Dinesh Jain as Global Chief Financial Officer.

Cipla Limited

Cipla Limited has announced its Q1 FY27 results, with revenue of INR 7,119 Cr, a 2% YoY growth, and EBITDA of INR 1,192 Cr, a 16.7% of income from operations. The company's One-India business grew at 12% YoY, while North America delivered quarterly revenue of $162 Mn. The company's net cash position is INR 9,494 Cr, with debt primarily consisting of lease liabilities and working capital requirements.

Cipla Limited

Cipla Limited has informed the Exchange about Investor Presentation. The presentation highlights the company's Q1FY27 performance, with revenue of INR 7,119 Cr, EBITDA of INR 1,192 Cr, and PAT of INR 789 Cr. The company has maintained its leadership in the chronic market and has launched new products, including Yurpeak, Duolin Syncrobreathe, and Doloneuron. The presentation also discusses the company's strategic focus on therapeutic areas such as respiratory, urology, anti-diabetes, and cardiac.

Cipla Limited

Cipla Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of ₹785.55 crores and earnings per equity share of ₹9.77.